Ascendis Pharma CFO buys 250 company shares

Ascendis Pharma A/S Executive Vice President and Chief Financial Officer Scott Thomas Smith executed an open-market purchase of 250 Ordinary Shares on May 29, 2026 at $223.32 per share.

Rhea-AI Filing Summary

Ascendis Pharma A/S Executive Vice President and Chief Financial Officer Scott Thomas Smith executed an open-market purchase of 250 Ordinary Shares on May 29, 2026 at $223.32 per share. Following this transaction, his directly held position increased to 4,267 Ordinary Shares.

Insider Trade Summary

Net Buyer: 250 shares

Net Buy 1 txn

Insider SMITH SCOTT THOMAS

Role EVP & Chief Financial Officer

Bought 250 shs ($56K)

Type	Security	Shares	Price	Value
Purchase	Ordinary Shares	250	$223.32	$56K

Holdings After Transaction: Ordinary Shares — 4,267 shares (Direct)

Key Figures

Shares purchased: 250 shares Purchase price: $223.32 per share Shares held after: 4,267 shares +1 more

4 metrics

Shares purchased 250 shares Open-market purchase on May 29, 2026

Purchase price $223.32 per share Open-market purchase of Ordinary Shares

Shares held after 4,267 shares Direct ownership following the transaction

Net buy shares 250 shares Net buy direction in this Form 4

Key Terms

Ordinary Shares, open-market purchase, transaction code P, direct ownership

4 terms

Ordinary Shares financial

"security_title: "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

open-market purchase financial

"transaction_action: "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

transaction code P financial

"transaction_code_description: "Purchase in open market or private transaction""

direct ownership financial

"ownership_type: "direct""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Ascendis Pharma (ASND) report on this Form 4?

Ascendis Pharma reported that EVP and CFO Scott Thomas Smith bought 250 Ordinary Shares in an open-market transaction. The purchase occurred on May 29, 2026 at a price of $223.32 per share.

How many Ascendis Pharma (ASND) shares did the CFO buy and at what price?

The CFO purchased 250 Ordinary Shares of Ascendis Pharma at $223.32 per share. This was an open-market transaction and increased his directly held stake in the company.

What are Scott Thomas Smith’s Ascendis Pharma (ASND) holdings after this trade?

After the reported open-market purchase, Scott Thomas Smith directly holds 4,267 Ascendis Pharma Ordinary Shares. The Form 4 reflects this updated ownership figure following the 250-share acquisition.

Was the Ascendis Pharma (ASND) CFO transaction a purchase or a sale?

The transaction was a purchase. The Form 4 classifies it as an open-market acquisition, with transaction code P and transaction direction marked as a buy of Ordinary Shares.

Did the Ascendis Pharma (ASND) Form 4 include any derivative transactions?

No, the filing only reports a non-derivative purchase of Ordinary Shares. The derivative transaction summary is empty, indicating no options, warrants, or other derivatives were transacted in this report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/01/2026 - 04:10 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SMITH SCOTT THOMAS

(Last) (First) (Middle)

C/O ASCENDIS PHARMA A/S

TUBORG BOULEVARD 12

(Street)

HELLERUP DK-2900

(City) (State) (Zip)

DENMARK

(Country)

2. Issuer Name and Ticker or Trading Symbol
Ascendis Pharma A/S [ ASND ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	05/29/2026		P		250	A	$223.32	4,267	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Michael Wolff Jensen as attorney-in-fact for Scott Smith	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)